Without relying on drug sales through consultations, revenue exceeds tens of millions: Huakang Medical Promotion paves a new path in digital and intelligent healthcare.
Currently, China's healthcare industry is standing at a critical juncture of structural transformation.
On the one hand, 1.055 million grassroots healthcare institutions support more than 50% of the outpatient volume nationwide in China. However, grassroots medical care still struggles with long-term issues such as talent shortages, weak capabilities, lack of trust, and inefficient services; on the other hand, pharmaceutical enterprises face challenges like centralized procurement cost control, stricter compliance requirements, and difficulties entering hospitals. In the current era of digital transformation, they urgently need to find new growth points. Grassroots medical care is generally regarded as a breakthrough for pharmaceutical companies to achieve growth.
Nowadays, the "15th Five-Year Plan" further emphasizes primary healthcare services as a key planning focus. The notice released on April 1st, titled "Three-Year Action Plan for Improving Medical Quality in Primary Healthcare Institutions (2026-2028)," places particular emphasis on medical quality and safety management in these institutions, setting clear tasks regarding management systems, personnel training, and critical diagnostic procedures.
The intensification of policies is undoubtedly expected to further expand the market. Better aligning primary healthcare with the pharmaceuticals industry, and improving the quality and efficiency of grassroots healthcare institutions, presents both an opportunity and a challenge.
Founded in 2020, Huakang Medical Promotion (Huakang Medical Promotion Health Technology (Beijing) Co., Ltd., hereinafter referred to as "Huakang Medical Promotion"), chose a different path—digitally empowering grassroots healthcare—at a time when the pandemic led to a surge in online consultations and internet healthcare companies were focused on providing online diagnosis and pharmaceutical e-commerce.
This is closely related to the personal experience of Tian Jin, CEO of Huakang Yicu. Having long been engaged in the research and development of digital solutions, she once created a hip surgery solution for Microsoft's HoloLens mixed reality device. She deeply realized that there is still a significant gap in digital healthcare solutions tailored to local medical staff.
By taking the enhancement of primary healthcare capabilities as the entry point, gradually covering the primary healthcare service network through public health screenings and other methods, and building a compliant service foundation with its self-developed consortium blockchain, Huakang Medical Promotion has achieved effective integration between grassroots healthcare initiatives and the pharmaceuticals industry. This has established a closed-loop system encompassing "enhancement of primary healthcare capabilities – precise empowerment of pharmaceutical and device enterprises – unlocking the value of medical data."
Let's look at a set of data first:
According to the "Statistical Communique of the People's Republic of China on the 2025 National Economic and Social Development," by the end of the year, there were 1.107 million healthcare institutions nationwide in China, with 1.055 million being grassroots healthcare institutions. Among them, there were 33,000 township health centers, 38,000 community health service centers (stations), 424,000 outpatient departments (clinics), and 560,000 village clinics. The National Health Commission once pointed out that "the proportion of diagnosis and treatment volume at grassroots healthcare institutions has consistently remained above 50% of the national total, and over 90% of residents in China can access nearby and convenient healthcare services within 15 minutes."
However, behind the gratifying scale of coverage lurks the challenge of aligning grassroots medical service capabilities with patient needs. This is mainly reflected in: an imbalanced talent structure, with a scarcity of highly skilled doctors. In an interview, CEO of Huakang Medical Promotion, Tian Jin, mentioned that by the end of 2025, a coastal developed province with a trillion-level GDP will have no hospital capable of performing cochlear implant surgeries in one of its prefecture-level cities. Meanwhile, this surgery has been promoted in China for over 20 years; insufficient patient trust leads to higher-level hospitals siphoning patients from grassroots facilities. This also makes it difficult to implement tiered medical treatment and crowds out resources for treating complex and severe cases; continuity of services inside and outside hospitals is lacking, and full-cycle chronic disease management is seriously deficient. Due to a lack of corresponding digital management tools at the grassroots level, long-term effective management of chronic disease patients cannot be achieved; limited access to high-quality equipment and medicines restricts service availability. Currently, a large number of grassroots healthcare institutions lack new diagnostic and treatment equipment, and innovative drugs and advanced therapeutic devices are still restricted in reaching grassroots facilities.
And with the improvement of IoT and the intelligence level of medical devices, Tian Jin realized that by building a digital healthcare platform, it could link the most advanced surgical solutions, allowing top doctors to better promote and teach at grassroots healthcare institutions, and bring high-quality surgical solutions to patients, addressing the current challenges faced by grassroots healthcare. Looking at the initiatives of Huakang Medical Promotion, they might be simply summarized into the following three major approaches:
One is to address the lack of expert resources and insufficient diagnostic capabilities at the grassroots level by leveraging high-quality medical resources.Huakang Medical Promotion has an exclusive strategic partnership with the China Medical Promotion Association. It boasts extensive expert resources and academic networks, aggregating over 10,000 renowned doctors across 16 disciplines within the association. By providing digital systems to grassroots healthcare institutions, it enables expert online remote consultation, report interpretation, treatment guidance, demonstration training, and more, allowing grassroots patients to access top-tier (Class III Grade A) expert services close to home while continuously enhancing the service capabilities of grassroots doctors.
The second is to use public health screening as an entry point to accelerate the "networking" and coverage of grassroots medical and health institutions.Relying on in-depth cooperation with local governments in Xinjiang, Yinchuan, and the China Medical Promotion Association, Huakang Medical Promotion has undertaken public health screening projects in multiple regions. Focusing on hearing screenings, ECG monitoring, and sleep monitoring, it has built an extensive grassroots medical service network, breaking down barriers between doctors and patients. Additionally, through a digital platform, it empowers grassroots doctors by enhancing their capabilities.
For example, in the 2024 Yinchuan "Ten Heartfelt Deeds — Sleep Well, Hear Clearly" livelihood project, Huakang Medical Promotion, as the cooperating executing party, fully leveraged its technical advantages in intelligent medical devices, AI analysis of medical test reports, and remote services, providing solid technical support for the project's implementation. The project successfully created a full-process service loop of "grassroots screening — intelligent diagnosis — expert consultation," exploring and forming a Yinchuan-characteristic public health management service model led by the government, coordinated by departments, supported by scientific research, managed throughout the entire cycle, and widely participated in by all citizens. At the same time, the project established a digital diagnosis and treatment service network covering the city, county, and township levels, serving tens of thousands of people cumulatively, forming a replicable and promotable operational model. Its successful experience has also been included in the National Health Commission's "Primary Healthcare Innovation Case Library."
In the 2025 Xinjiang Hearing Screening, Huakang Medical Promotion organized relevant experts to conduct training at Karamay Central Hospital.
Currently, Huakang Medical Promotion has built five vertical disease networks on its own Internet hospital: including the 18-lead dynamic ECG monitoring network (with 4500+ participating institutions), intelligent auditory health monitoring network, non-invasive hemodynamic monitoring network, dynamic blood pressure monitoring network, remote sleep monitoring network, and more. Based on the occupation of core scenarios in grassroots digital and intelligent operations, Huakang Medical Promotion aims to serve 600,000 patients by 2025.
The third is to build a digital healthcare alliance chain, enabling doctors, patients, and even enterprises to achieve effective resource utilization.Based on the consortium blockchain, several major problems have been effectively solved: First, it promotes the online activity of offline doctors. Through measurable services, quantifiable contributions, and automatic profit settlement, experts are willing to use fragmented time to remotely empower grassroots levels and obtain transparent and reasonable income. Second, it realizes data rights confirmation, solving the problem of data being "unable to use, or too risky to use." The consortium blockchain accurately marks the subject of each piece of data through on-chain certification, immutability, and unique traceability, making the data usable. Third, based on the usability of data, it achieves compliance in scientific research. Whether for real-world research, post-marketing evaluation of drugs, or clinical data support, the consortium blockchain can provide compliant, desensitized, traceable, and high-quality data foundations while balancing patient privacy protection, doctor intellectual property rights, and corporate research needs.
In the 2025 Ningxia "Data Element x Competition," Huakang Yicu was the only private enterprise to enter the finals of the competition.
From the下沉 of expert doctor resources, to the 上线 of grassroots healthcare institutions, to the compliant utilization of the value of doctor-patient data generated during the medical service process, Huakang Medical Promotion has built a solid digital foundation and a sustainable healthcare service system.
The construction of the medical service system has also enabled Huakang Medical Promotion to help pharmaceutical enterprises find their second growth curve.
The reason lies in the lack of high-quality medical device products at the grassroots healthcare level. In addition to insufficient medical service capabilities, primary care also lacks high-quality, intelligent, and cost-effective medical devices. Meanwhile, pharmaceutical and device companies are seeking compliant ways to reach grassroots healthcare institutions in order to achieve long-term patient management, obtain real-world data, and enhance academic influence. Huakang Medical Promotion, leveraging its own capabilities, has become the core hub linking these two parties, ultimately creating a win-win situation where "grassroots healthcare is empowered, patients receive benefits, doctors grow professionally, and pharmaceutical companies gain market access."
Huakang Medical Promotion Invited to Attend the 2024 Computational Power Capital Developer Conference and Sign Cooperation Agreements with iFlytek, Ningxia Telecom, and Other Enterprises
From the perspective of Huakang Medical Promotion, it currently provides an end-to-end service system for pharmaceutical and medical device companies. The existing diagnostic products within Huakang Medical Promotion's service network can already preliminarily meet the needs of grassroots healthcare institutions, and the organization is still seeking more partnerships for intelligent medical devices.
In the Yinchuan Minsheng Project, staff use intelligent hearing detection equipment to analyze test data.
Tian Jin introduced that Huakang Medical Promotion (Yicu) is currently shifting its focus from serving medical device companies to further serving pharmaceutical enterprises. Huakang Yicu has considered that: pharmaceutical enterprises are currently facing survival pressures, and the grassroots level is extremely lacking in high-quality medicines. It hopes to improve the current situation by cooperating with more pharmaceutical enterprises. Overall, Huakang Yicu can empower pharmaceutical enterprises in the following aspects——
At the patient management level, Huakang Medical Promotion can provide ultra-long-term intelligent follow-ups, maximize clinical value, and accumulate high-quality doctor-patient service data to support product promotion and post-launch optimization.In the past, due to low patient medication adherence and behaviors such as self-initiated discontinuation of treatment, the actual value of medications often went unassessed, while the trust gap between doctors and patients widened. However, with the help of digital tools like wearable devices, smart pillboxes, and electronic scales, platforms can now collect real-time physiological indicators and medication data from patients. This allows for the creation of personalized health management records for each patient, enabling dynamic health monitoring and intelligent follow-ups. Moreover, based on AI technology, these platforms can generate customized plans to achieve personalized, long-term management.
At the R&D level, the platform can empower research and development based on real-world study data.Based on the extensive data of patient medication efficacy, recurrence rates, and side effects accumulated on its platform, Huakang Yicu can further assist pharmaceutical companies in achieving R&D goals. Additionally, leveraging vast amounts of data, Huakang Yicu can uncover unmet needs from past clinical practices, enabling pharmaceutical companies to conduct R&D that aligns with market demands. Moreover, based on Huakang Yicu's five major vertical disease networks, it can also meet pharmaceutical companies' requirements for precise patient recruitment during clinical trials, as well as the collection and analysis of patient data both inside and outside hospitals.
At the academic promotion level, assist in compliant academic promotion.Huakang Medical Promotion possesses a professional academic activity initiation team, maintaining long-term academic exchanges with over 5,000 renowned doctors and establishing in-depth cooperation with more than 5,000 hospitals across China. Additionally, over a hundred new cooperative hospitals are added each month. Relying on these resources, Huakang Medical Promotion can provide pharmaceutical enterprises with top-level academic promotion and specialized multi-center construction services. Through the alliance chain, the entire process of academic promotion and patient education is traceable, greatly addressing compliance issues.
In terms of market coverage, the platform can enhance the efficiency of enterprises' grassroots market coverage.Huakang Medical Promotion integrates resources, allowing pharmaceutical companies to quickly leverage its supply chain to cover the grassroots market. Moreover, Huakang Medical Promotion also has an online Internet hospital, which is expected to achieve comprehensive reach for pharmaceutical companies in both online and offline scenarios targeting grassroots patients.
Based on the gradual formation of the above-mentioned chain, Huakang Medical Promotion has formed three major businesses: providing digital solutions for grassroots medical institutions, public health screening projects for the government sector, and empowering pharmaceutical and medical device enterprises.
Jin Tian, CEO of Huakang Medical Promotion, added that the empowerment of pharmaceutical and medical device companies is becoming a new growth engine for Huakang Medical Promotion. According to reports, Huakang Medical Promotion has already reached cooperation with a large number of pharmaceutical and medical device enterprises. Currently, the company's revenue has reached an inflection point: in the first quarter of 2026, Huakang Medical Promotion's revenue exceeded 30 million yuan, surpassing the total revenue of 2025.With the rapid growth of revenue, Huakang Medical Promotion is expected to break through 100 million yuan in revenue by the end of 2026, with significantly increased certainty of revenue growth.
For Huakang Medical Promotion, the growth is an inevitable result of industry development. As primary healthcare services are increasingly valued by the state and policies continue to strengthen, future government public health investment will further increase. Meanwhile, pharmaceutical companies, in order to comply with regulations while expanding their markets, are showing a significantly enhanced willingness to pay. Moreover, the digital medical alliance chain and platform built by Huakang Medical Promotion will further integrate technologies such as AI, effectively meeting industry demands while continuously improving service efficiency and customer experience. Tian Jin stated,Huakang Medical Promotion plans to initiate financing in the second half of 2026, further broadening its barriers by introducing high-quality industrial capital.
In the future, with the continuous improvement of grassroots medical capabilities, the deepening advancement of digital transformation in the pharmaceutical industry, and the increasing value release of medical data elements, platforms like Huakang Medical Promotion (Huakang Yicu), which focus on grassroots services, compliant operations, and value creation, will embrace broader development opportunities. At the same time, they are bound to contribute significantly to the enhancement of primary healthcare service quality for grassroots doctors.